Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
Milind Javle(The University of Texas MD Anderson Cancer Center), Mitesh J. Borad(Mayo Clinic in Arizona), Nilofer S. Azad(Johns Hopkins Medicine), Razelle Kurzrock(University of California, San Diego), Ghassan K. Abou‐Alfa(Memorial Sloan Kettering Cancer Center), Ben George(Medical College of Wisconsin), John D. Hainsworth(Tennessee Oncology), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Charles Swanton(The Francis Crick Institute), Christopher J. Sweeney(Harvard University), Claire F. Friedman(Memorial Sloan Kettering Cancer Center), Ron Bose(Washington University in St. Louis), David R. Spigel(Sarah Cannon), Yong Wang, Jonathan Levy, Katja Schulze, Vaikunth Cuchelkar, Arisha Patel, Howard A. Burris(Tennessee Oncology)
Cited by 400
Abstract
Related Papers
No related papers found
Powered by citation graph analysis